EODData

MEMBERSHIP REGISTER LOG IN

FRA, 4AB: AbbVie Inc

05 Nov 2025
LAST:

186.6

CHANGE:
 4.20		OPEN:
187.0		HIGH:
187.0		ASK:
0.0		VOLUME:
24
CHG(%):
2.30		PREV:
182.4		LOW:
186.6		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 25187.0187.0186.6186.624
04 Nov 25182.4182.4182.4182.4200
31 Oct 25194.8198.2188.0188.0403
30 Oct 25192.8197.0192.8197.0184
29 Oct 25194.8195.0192.8195.0211
28 Oct 25194.6195.2194.0195.211
27 Oct 25195.6195.6195.6195.65
24 Oct 25195.8197.6195.8197.651
23 Oct 25196.2196.2196.2196.283
22 Oct 25198.2198.8198.2198.883

COMPANY PROFILE

Name:AbbVie Inc
About:AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sector:Healthcare
Address:1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Website:https://www.abbvie.com
ISIN:US00287Y1091
LEI:FR5LCKFTG8054YNNRU85

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:160.87 
Forward P/E:13.24 
PEG Ratio:-5.18 
Price to Sales:5.49 
Price to Book:-2,334.80 
Profit Margin:0.04 
Operating Margin:0.36 
Return on Assets:0.03 
Return on Equity:1.26 
DivYield:0.04 
Div/Share:6.47 
Revenue:51.765B 
EBITDA:14.695B 
Shares:1.767B 
Market Cap:329.64B 

TECHNICAL INDICATORS

MA5:189.801.7%
MA10:193.243.6%
MA20:195.714.9%
MA50:189.161.4%
MA100:176.955.5%
MA200:176.405.8%
STO9:26.58
STO14:24.42
RSI14:34.95 
WPR14:-75.58
MTM14:-7.80
ROC14:-0.04 
ATR:3.26 
Week High:198.206.2%
Week Low:182.402.3%
Month High:202.008.3%
Month Low:182.405.8%
Year High:209.5012.3%
Year Low:145.9627.8%

RECENT DIVIDENDS

Date Amount
15 Oct 2025$1.41
15 Jul 2025$1.41
15 Apr 2025$1.41
15 Jan 2025$1.41
15 Oct 2024$1.33
15 Jul 2024$1.33
12 Apr 2024$1.33
12 Jan 2024$1.33
12 Oct 2023$1.27
13 Jul 2023$1.27